24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Diabetes
Resources
Basic InformationLatest News
Mapping IDs Geographic Access Barriers for Diabetic RetinopathyNormal Meal Tolerance Test Is Practical, Reliable in T2DMNo Link to Cognition in Diabetes Prevention Program StudySuicide by Insulin?Promising Start for National Diabetes Prevention ProgramDiabetes Drug Gets FDA Warning Due to Amputation RiskAngela Bassett Puts the Spotlight on Heart HealthAs Temps Rise, Risk of Pregnancy Complication May TooPharmacist-Involved Collaborative Care Benefits T2DMNever Breastfeeding Linked to Increased Risk of T1DMBioengineered Intraabdominal Endocrine Pancreas FeasibleBiomarker ID'd for Pregnancy-Induced Glucose IntoleranceTransplant of Insulin-Producing Cells Offers Hope Against Type 1 DiabetesVitamin D Doesn't Impact Insulin Sensitivity, Secretion in T2DMPCSK9 Linked to New-Onset Diabetes After Renal TransplantLinear Association for Weight Loss, HbA1c Reduction in T2DMHealth Tip: Make Food More FlavorfulAntioxidant Resveratrol May Help Reduce Arteriosclerosis in T2DMHealth Tip: Create a Sick-Day Plan for DiabetesRed Wine Antioxidant Might Help Diabetics' ArteriesCardiometabolic Disease Staging Score Quantifies Diabetes RiskIntense Interval Training Cuts Hypoglycemia Awareness in T1DMDecreased Cortical Thickness Seen in Type 2 DiabetesAlgorithm Integrated Into App Forecasts Glucose LevelsThree Anti-VEGF Treatments Effective for Diabetic RetinopathyType 2 Diabetes May Be Bad for Brain HealthHealth Tip: Coping With the 'Dawn Phenomenon'Plasma Uric Acid Lowering Tied to Drop in Systolic BP in T1DMHealth Tip: Continuous Glucose Monitoring DevicesT2DM Risk Cut by Variant in Sulfonylurea Receptor EncoderObesity Quadruples Kids' Type 2 Diabetes Risk: StudyDoctors Encouraged to Assess Driving Risks for T1DM PatientsEarly Glycemic Control With Metformin Cuts CVD EventsWhen Is It Safe to Drive With Type 1 Diabetes?Nurse-Led Intervention Helps With Diabetes ControlIs Annual Eye Exam a Must for People With Type 1 Diabetes?RUNX1 May Play Role in Proliferative Diabetic RetinopathyFast-Acting Insulin Aspart Ups Glycemic Control in T1DMDiabetes Continues to Be a Significant Public Health BurdenContinuous Glucose Monitoring Improves Quality of Life in T1DMDiabetes Continues Its Relentless RiseContinuous Subcutaneous Insulin Infusion Bests Injections in T2DMPrevalence of Metformin Use 0.7 Percent in PrediabetesENDO: Distinct Urine Metabolite Profile in Obese Youth With T2DMRace Plays Role in Heart, Diabetes Risk, Even at Normal WeightPredictive Low-Glucose Mgmt Cuts Hypoglycemic Events in T1DTeleretinal Diabetic Retinopathy Screening Ups Screening RatesDAPT Cessation Patterns Vary With Diabetes Status After PCIIncreased Use of Newer Meds for Diabetic Nephropathy in the U.S.What Drugs Work Best for Diabetic Nerve Pain?
Links
Related Topics

Medical Disorders

Predictive Low-Glucose Mgmt Cuts Hypoglycemic Events in T1D


HealthDay News
Updated: Mar 31st 2017

new article illustration

FRIDAY, March 31, 2017 (HealthDay News) -- For children with type 1 diabetes, use of the predictive low-glucose management (PLGM) feature of the MiniMed 640G system is associated with a reduced number of hypoglycemic events, according to a study published online March 28 in Diabetes Care.

Tadej Battelino, M.D., from the University Children's Hospital in Ljubljana, Slovenia, and colleagues conducted a randomized trial involving 100 children and adolescents with type 1 diabetes and glycated hemoglobin A1c ≤10 percent and using continuous subcutaneous insulin infusion. Participants were randomized in a 1:1 ratio to an intervention group with PLGM features enabled (PLGM ON) or a control group (PLGM OFF).

The researchers found that the PLGM ON group had a significantly smaller number of hypoglycemic events <65 mg/dL compared with the PLGM OFF group (mean ± standard deviation: 4.4 ± 4.5 versus 7.4 ± 6.3; P = 0.008). The finding persisted when the events were calculated separately for night and day (P = 0.025 and 0.022, respectively). There were no severe hypoglycemic events; in the PLGM ON group there was an increase in time spent >140 mg/dL (P = 0.0165).

"The PLGM insulin suspension was associated with a significantly reduced number of hypoglycemic events," the authors write. "Although this was achieved at the expense of increased time in moderate hyperglycemia, there were no serious adverse effects in young patients with type 1 diabetes."

Several authors disclosed financial ties to pharmaceutical and medical device companies, including Medtronic, which manufactures the MiniMed 640G system and funded the study.

Abstract/Full Text (subscription or payment may be required)